Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts. Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a Phase Ia clinical trial product for chronic HCV infection; VX-985, which is under preclinical trails for chronic HCV infection; VX-770, a Phase IIa clinical trial candidate for the treatment of Cystic fibrosis; VX-809, a Phase Ib clinical trial product for the treatment of Cystic fibrosis; VX-509, a Phase Ia clinical trial product for immune-mediated inflammatory diseases; MK-5108 (VX-689), a Phase I clinical trial product for the treatment of cancer; and AVN-944(VX-944), which is in Phase 2 clinical trial for the treatment of cancer. The company also has development and commercial rights to VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases. It has collaboration agreements with Janssen Pharmaceutica, N.V.; Mitsubishi Tanabe Pharma Corporation; Cystic Fibrosis Foundation Therapeutics Incorporated; Merck & Co., Inc.; Avalon Pharmaceuticals, Inc.; GlaxoSmithKline plc.; and Bend Research Inc.
Contact Details
Office Address
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA, USA 02139
Phone: (617) 444-6100
Fax: (617) 576-2109
Executives
Chairman, Chief Exec. Officer and Pres.
Mr. Matthew Emmens
Founder and Exec. Director
Dr. Joshua S. Boger
.webp)
.webp)
.webp)
.webp)
.webp)
